Michael W. Bonney

Companies

• IMMUNIC, INC.Board member May 19, 2026 to now¹
• Autolus TherapeuticsBoard member Mar 18, 2026 to now²
• Alnylam PharmaceuticalsBoard member Dec 18, 2014 to now³
• Alnylam PharmaceuticalsChair Aug 3, 2021 to Aug 3, 2021⁴
• Kaleido Biosciences, Inc.Board member Jul 1, 2020 to Jul 1, 2021⁵
• Bristol-Myers SquibbBoard member Nov 22, 2019 to Jul 1, 2021⁶
• Magenta TherapeuticsBoard member Jun 20, 2018 to Jun 3, 2021⁷
• Sarepta TherapeuticsBoard member Dec 5, 2017 to Feb 28, 2020⁸
• Syros Pharmaceuticals, Inc.Board member Jun 15, 2018 to Jun 12, 2019⁹
• Kaleido Biosciences, Inc.Chair Feb 27, 2019 to Mar 4, 2019¹⁰
• Global Blood Therapeutics, Inc.Board member Feb 10, 2016 to Jun 17, 2016¹¹
• abrdn World Healthcare FundBoard member Jun 25, 2015 to Aug 18, 2015¹²
• NPS Pharmaceuticals (United States)Board member Jan 19, 2006 to Feb 24, 2015¹³
• Cubist PharmaceuticalsBoard member Jan 5, 2006 to Jan 21, 2015¹⁴
• Cubist PharmaceuticalsChief executive officer Jan 5, 2006 to Jan 21, 2015¹⁴
• abrdn Healthcare Opportunities FundBoard member Jul 28, 2014 to Jul 29, 2014¹⁵
• abrdn Healthcare InvestorsBoard member Dec 15, 2011 to Jun 30, 2014¹⁶
• abrdn Life Sciences InvestorsBoard member Dec 15, 2011 to Jun 30, 2014¹⁷
• Cubist PharmaceuticalsPresident Jan 5, 2006 to Feb 20, 2013¹⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Alnylam Pharmaceuticals ALNY20,804 shares¹⁸$4.9M at $235.58Aug 19, 2025
• Bristol-Myers Squibb BMY14,501 shares¹⁹$865.3K at $59.67Jun 14, 2021

As of each latest filing. The line shows shares held over time.

Recent filings

• Aug 18, 2025Sold 11,250 shares at $450.00 of Alnylam Pharmaceuticals¹⁸
• Aug 18, 2025Exercised options 11,250 shares at $70.20 of Alnylam Pharmaceuticals¹⁸
• May 15, 2025Sold 1,617 shares at $283.83 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 1,728 shares at $282.81 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 802 shares at $282.03 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 372 shares at $281.10 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 432 shares at $280.03 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 1,239 shares at $278.01 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 1,263 shares at $277.16 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 301 shares at $275.63 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 882 shares at $273.75 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 660 shares at $273.16 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 431 shares at $271.68 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 245 shares at $269.79 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 729 shares at $268.56 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Sold 549 shares at $267.14 of Alnylam Pharmaceuticals²⁰
• May 15, 2025Exercised options 11,250 shares at $131.21 of Alnylam Pharmaceuticals²⁰
• May 8, 2025Granted 775 shares of Alnylam Pharmaceuticals²¹
• Dec 27, 2023Sold 30,000 shares at $195.00 of Alnylam Pharmaceuticals²²
• Dec 27, 2023Exercised options 30,000 shares at $96.45 of Alnylam Pharmaceuticals²²
• Aug 3, 2023Sold 450 shares at $187.71 of Alnylam Pharmaceuticals²³
• Aug 3, 2023Sold 1,389 shares at $187.04 of Alnylam Pharmaceuticals²³
• Aug 3, 2023Sold 1,714 shares at $185.99 of Alnylam Pharmaceuticals²³
• Aug 3, 2023Sold 1,535 shares at $184.89 of Alnylam Pharmaceuticals²³
• Aug 3, 2023Sold 560 shares at $183.75 of Alnylam Pharmaceuticals²³

Trade performance

Returns are price-only (no dividends), measured from the trade date.